Prenetics Global (PRE, Financial) experienced a significant increase in stock price, rising by 9.50%, reaching $4.38 per share. The trading volume stood at 11,226 shares with a turnover rate of 0.09%, and the stock's amplitude was noted at 8.25%.
Recent financial reports show that the company achieved a revenue of $6.41 million, with a net loss of $8.54 million, translating to an earnings per share (EPS) of -$0.70 and a gross profit of $3.78 million. The price-to-earnings (P/E) ratio is recorded at -0.83.
Regarding institutional ratings, one rating institution has participated, giving a 100% buy recommendation for the stock. No institutions have issued a hold or sell recommendation.
Within the life sciences industry, Prenetics Global's sector saw an overall decline of 0.71%. However, related stocks such as Prenetics Global Limited C/Wts 18/05/2027 (To Pur Com) and Volitionrx Limited showed significant gains. Active stocks in the sector included Applied Dna Sciences, Inc., Ispecimen Inc., and Mainz Biomed N.V., with turnover rates of 155.67%, 6.84%, and 6.12%, respectively. Stocks with notable amplitude include Prenetics Global Limited C/Wts 18/05/2027 (To Pur Com) with 35.19%, Applied Dna Sciences, Inc. at 21.50%, and Volitionrx Limited at 11.63%.
Prenetics Global Ltd is a diagnostics and genetic testing company dedicated to bringing comprehensive, accessible preventive, diagnostic, and personalized care to millions globally. Their operations span nine regions, including the UK, Hong Kong, India, South Africa, and Southeast Asia. The company focuses on consumer genetic testing, early colorectal cancer screening, COVID-19 testing, rapid care point and home diagnostics, and medical genetic testing.
